Factor Report

Data as of market close on 8/12/2022.

Validea's factor report analyzes any stock using the major investing factors, including value, quality, momentum, and low volatility.
View User Guide    Video Tutorial

CARA THERAPEUTICS INC (CARA)

View Guru Analysis
Latest Close: $11.51 Market Cap ($ mil): $618 Sector: Services Industry: Business Services 52 Week High: $18.93 52 Week Low: $7.40 Relative Strength: 53 Twelve Minus One Return: -27.9% Standard Deviation: 66.3%
PE Ratio: N/A Price/Sales: 12.7 Price/Book: 3.0 Price/Cash Flow: N/A EV/EBITDA: N/A Yield: N/A Shareholder Yield: -13.12% F Score: 2 G Score: 2
Return on Equity: -32.5% Return on Assets: -29.6% Return on Tangible Capital: -29.5% Return on Invested Capital: N/A WACC: 7.2% Debt/Equity: 0.00 LT EPS Growth: N/A LT Sales Growth: 115.6% Beta: 1.03
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates. The Company also initiated a pharmacokinetic safety trial of multiple doses of Oral CR845 in hemodialysis patients to define bioequivalent tablet strengths to inform its ability to develop an oral tablet formulation for moderate-to-severe uremic pruritus. CR701 is a peripherally restricted, mixed-CB1/CB2 receptor agonist that selectively interacts with these cannabinoid receptor subtypes, with no off-target activities.

Factor Profile

CARA's exposure to the major factors (100 is highest).

Comparable Stocks

Stocks with the closest factor profiles to CARA.

(click ticker to access stock report and name to view guru analysis)

Ticker Ticker
BTAI ORC
ANAB ZYME
STRO HYLN
Performance Disclaimer: Returns presented on Validea.com are model returns and do not represent actual trading. As a result, they do not incorporate any commissions or other trading costs or fees. Model portfolios with inception dates on or after 12/30/2005 include a combination of back tested and live model returns. The back-tested performance results shown are hypothetical and are not the result of real-time management of actual accounts. The back-testing of performance differs from actual account performance because the investment strategy may be adjusted at any time, for any reason and can continue to be changed until desired or better performance results are achieved. Back-tested returns are presented to provide general information regarding how the underlying strategy behind the portfolio performed in our historical testing. A back-tested strategy has the benefit of hindsight and the results do not reflect the impact that material economic or market factors may have had on advisor's decision-making if actual client assets were being managed using this approach. The model portfolios offered on Validea are concentrated and as a result they will exhibit high levels of volatility and their performance can be substantially impacted by the performance of individual positions.

Optimal portfolios presented on Validea.com represent the rebalancing period that has led to the best historical performance for each of our equity models. Each optimal portfolio was determined after the fact with performance information that was not available at portfolio inception. As a result, an investor could not have invested in the optimal portfolio since its inception. Optimal portfolios are presented to allow investors to quickly determine the portfolio size and rebalancing period that has performed best for each of our models in our historical testing.

Both the model portfolio and benchmark returns presented for all equity portfolios on Validea.com are not inclusive of dividends. Returns for our ETF portfolios and trend following system, and the benchmarks they are compared to, are inclusive of dividends. The S&P 500 is presented as a benchmark because it is the most widely followed benchmark of the overall US market and is most often used by investors for return comparison purposes. As with any investment strategy, there is potential for profit as well as the possibility of loss and investors may incur a loss despite a past history of gains. Past performance does not guarantee future results. Results will vary with economic and market conditions.